---
title: "Longview Tea Company Ltd (526568) — Share Price, Financials & Analysis"
symbol: "526568"
company: "Longview Tea Company Ltd"
canonical: "https://tapetide.com/stocks/526568"
bse_code: "526568"
sector: "Fast Moving Consumer Goods"
industry: "Agricultural Food & other Products"
generated_at: "2026-09-13T18:59:10.150Z"
---

# Longview Tea Company Ltd (526568)

Canonical page: https://tapetide.com/stocks/526568

## Company

- **BSE Code:** 526568
- **Sector:** Fast Moving Consumer Goods
- **Industry:** Agricultural Food & other Products
- **Macro Sector:** Fast Moving Consumer Goods
- **Stock Type:** EQUITY
- **Listed Since:** 2009-05-27
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** longviewtea.org

## About

Incorporated in 1879, Longview Tea Company 
Ltd is in the business of trading commodities and dealing in financial activities.[1]

## Latest Price

## Key Insights

### Strengths

- Company is almost debt free.
- Stock is trading at 0.24 times its book value

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -4.98%
- Promoter holding is low: 39.4%
- Company has a low return on equity of 1.23% over last 3 years.

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| net income growth | -115% | -59% | -2% |
| revenue growth | -70% | 14% | 34% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0.3 | 0.33 | 0 | 0.45 | 0.72 | 0 | 1.02 | 0.82 | 0 | 0 | 0 | 0.78 |
| Expenses | 0.24 | 0.36 | 0.07 | 0.52 | 0.82 | 0.13 | 1.11 | 0.89 | 0.01 | 0.4 | 0.25 | 0.81 |
| Operating Profit | 0.06 | -0.03 | -0.07 | -0.07 | -0.1 | -0.13 | -0.09 | -0.07 | -0.01 | -0.4 | -0.25 | -0.03 |
| OPM % | 20 | -9.09 | — | -15.56 | -13.89 | — | -8.82 | -8.54 | — | — | — | -3.85 |
| Other Income | 0.2 | 0.19 | 0.62 | 0.48 | 0.72 | 0.43 | 0.9 | 0.57 | 0.04 | -0.41 | 0.88 | 0.05 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Profit before tax | 0.25 | 0.15 | 0.54 | 0.4 | 0.61 | 0.29 | 0.8 | 0.49 | 0.02 | -0.82 | 0.62 | 0.01 |
| Tax % | 32 | 140 | 11.11 | 20 | 16.39 | 27.59 | 26.25 | 46.94 | -650 | -18.29 | 59.68 | -200 |
| Net Profit | 0.17 | -0.06 | 0.47 | 0.33 | 0.51 | 0.21 | 0.58 | 0.26 | 0.15 | -0.67 | 0.25 | 0.03 |
| EPS in Rs | 0.57 | -0.2 | 1.57 | 1.1 | 1.7 | 0.7 | 1.94 | 0.87 | 0.5 | -2.24 | 0.83 | 0.1 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0.5 | 0.57 | 0 | 0.42 | 1.15 | 1.23 | 1.36 | 1.17 | 1.83 | 0.78 |
| Expenses | 1.23 | 1.24 | 0.74 | 0.81 | 4.01 | 1.59 | 1.84 | 1.56 | 2.42 | 1.47 |
| Operating Profit | -0.73 | -0.67 | -0.74 | -0.39 | -2.86 | -0.36 | -0.48 | -0.39 | -0.59 | -0.69 |
| OPM % | -146 | -117.54 | — | -92.86 | -248.7 | -29.27 | -35.29 | -33.33 | -32.24 | -88.46 |
| Other Income | 0.79 | 0.94 | 0.8 | 0.81 | 0.98 | 5.46 | 0.58 | 2.26 | 1.1 | 0.56 |
| Interest | 0.06 | 0.06 | 0 | 0 | 0 | 0.03 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0.01 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 |
| Profit before tax | 0 | 0.21 | 0.06 | 0.42 | -1.89 | 5.04 | 0.06 | 1.83 | 0.47 | -0.17 |
| Tax % | — | 90.48 | 50 | 26.19 | -19.58 | 25.79 | 383.33 | 16.39 | 31.91 | — |
| Net Profit | -0.01 | 0.02 | 0.02 | 0.31 | -1.51 | 3.74 | -0.16 | 1.52 | 0.32 | -0.24 |
| EPS in Rs | -0.03 | 0.07 | 0.07 | 1.03 | -5.04 | 12.48 | -0.53 | 5.07 | 1.07 | -0.81 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 11.04 | 10.96 | 11 | 11.2 | 9.68 | 13.45 | 13.28 | 14.81 | 15.14 | 15.44 |
| Borrowings | 0.6 | 0 | 0 | 0 | 0 | 0.14 | 0.05 | 0 | 0 | 0 |
| Other Liabilities | 0.44 | 0.99 | 0.35 | 0.1 | 0.03 | 0.08 | 0.04 | 0.24 | 0.19 | 0.54 |
| Total Liabilities | 15.08 | 14.95 | 14.35 | 14.3 | 12.71 | 16.67 | 16.37 | 18.05 | 18.33 | 18.98 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0.31 | 0.28 | 0.35 | 0.31 | 0.27 | 0.25 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 8.62 | 6.35 | 6.22 | 5.8 | 3.12 | 7.06 | 6.14 | 7.85 | 6.27 | 6.63 |
| Other Assets | 6.46 | 8.6 | 8.13 | 8.5 | 9.28 | 9.33 | 9.88 | 9.89 | 11.79 | 12.1 |
| Total Assets | 15.08 | 14.95 | 14.35 | 14.3 | 12.71 | 16.67 | 16.37 | 18.05 | 18.33 | 18.98 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -0.73 | -0.82 | -0.55 | -1.47 | -1.08 | -0.16 | 2.85 | -0.41 | -0.4 | -0.41 |
| Cash from Investing Activity | 1.12 | 0.73 | 1.26 | 1.47 | 1.09 | 0.22 | -3.07 | 0.54 | 0.41 | 0.46 |
| Cash from Financing Activity | -0.09 | -0.24 | -0.71 | 0 | 0 | 0 | 0.13 | -0.1 | -0.06 | 0 |
| Net Cash Flow | 0.3 | -0.33 | 0 | 0 | 0.01 | 0.06 | -0.09 | 0.03 | -0.05 | 0.06 |
| Free Cash Flow | -0.73 | -0.82 | -0.55 | -1.47 | -1.08 | -0.48 | 2.84 | -0.51 | -0.41 | -0.41 |
| CFO/OP | 105 | 105 | 7 | 188 | 249 | 5 | -1000 | 62 | 108 | 14 |

### Ratios

| Item | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 14.6 | 116.8 | 0 | — | 147.74 | 0 | 0 | 0 | 0 | 0 |
| Inventory Days | 0 | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Conversion Cycle | 14.6 | 116.8 | 0 | — | 147.74 | 0 | 0 | 0 | 0 | 0 |
| Working Capital Days | 3104.93 | 4109.9 | 3726.84 | — | 6865.48 | 2548.65 | 2552.03 | 2493.27 | 2866.97 | 2060.36 |
| ROCE % | 3.38 | 0.08 | 1.4 | 0.36 | 2.7 | -15.55 | 33.69 | 2.13 | 10.19 | 1.95 |

## Shareholding Pattern

### annual

| Category | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 44.29% | 44.29% | 44.29% | 44.29% | 44.37% | 44.37% | 44.38% | 44.38% | 44.38% | 44.38% | 39.4% |
| DIIs | 3.82% | 3.82% | 3.82% | 3.82% | 3.81% | 3.6% | 3.51% | 3.5% | 3.5% | 3.28% | 3.28% |
| Public | 51.9% | 51.9% | 51.9% | 51.89% | 51.81% | 52.03% | 52.12% | 52.13% | 52.14% | 52.35% | 57.33% |
| No. of Shareholders | 8424 | 8236 | 8134 | 8076 | 8005 | 8099 | 8341 | 8291 | 8370 | 8343 | 8345 |

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 44.38% | 44.38% | 44.38% | 44.38% | 44.38% | 44.38% | 44.38% | 44.38% | 44.38% | 44.38% | 44.38% | 39.4% |
| DIIs | 3.51% | 3.51% | 3.5% | 3.5% | 3.5% | 3.5% | 3.5% | 3.28% | 3.28% | 3.28% | 3.28% | 3.28% |
| Public | 52.12% | 52.13% | 52.13% | 52.13% | 52.14% | 52.14% | 52.14% | 52.36% | 52.36% | 52.36% | 52.35% | 57.33% |
| No. of Shareholders | 8317 | 8289 | 8291 | 8288 | 8275 | 8328 | 8370 | 8355 | 8359 | 8344 | 8343 | 8345 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 5 / 3 / 11

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 186.95 | Sell |
| EMA (10) | 186.38 | Sell |
| SMA (20) | 189.39 | Sell |
| EMA (20) | 187.17 | Sell |
| SMA (50) | 187.02 | Sell |
| EMA (50) | 186.13 | Sell |
| SMA (100) | 184.37 | Sell |
| EMA (100) | 185.1 | Sell |
| SMA (200) | 193.46 | Sell |
| EMA (200) | 171.34 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 48.14 | Neutral |
| MACD (12,26,9) | -0.32 | Sell |
| Stochastic (14,3,3) | 13.24 | Buy |
| ADX (14) | 15.82 | Neutral |
| Williams %R (14) | -89.25 | Buy |
| ATR (14) | 11.88 | High Volatility |
| ROC (12) | -5.57 | Sell |
| Stoch RSI (14) | 8.19 | Buy |
| UO (7,14,28) | 27.59 | Buy |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 7 Apr - Submitted Regulation 74(5) compliance certificate for quarter ended March 31, 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Apr - Submitted Regulation 74(5) compliance certificate for quarter ended March 31, 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a0d30951-a8e6-46ea-9a6e-d923ae48fa18.pdf) |
| 7 Apr - Submitted Regulation 74(5) compliance certificate for quarter ended March 31, 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Apr - Submitted Regulation 74(5) compliance certificate for quarter ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a0d30951-a8e6-46ea-9a6e-d923ae48fa18.pdf) |
| 6 Jan - Ms. Jyoti resigned as Company Secretary and Compliance Officer effective 06.01.2026; no board since 28.11.2025. | [Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer 6 Jan - Ms. Jyoti resigned as Company Secretary and Compliance Officer effective 06.01.2026; no board since 28.11.2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/acaff738-2f1e-43b0-88e4-654dd3c292e8.pdf) |
| 28 Feb - BSE and NSE each fined Eris ₹65,000 on Feb 27, 2026 for Regulation 17(1) board composition non-compliance. | [Imposition Of Fine By BSE Limited And National Stock Exchange Of India Limited 28 Feb - BSE and NSE each fined Eris ₹65,000 on Feb 27, 2026 for Regulation 17(1) board composition non-compliance.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/45261d1c-1f08-4e30-b924-f23c7612c38a.pdf) |
| 27 Feb - Board dissolved since 28.11.2025; CS and CFO resigned Jan 2026; Q3 results (31.12.2025) pending; NCLT litigation. | [General Update 27 Feb - Board dissolved since 28.11.2025; CS and CFO resigned Jan 2026; Q3 results (31.12.2025) pending; NCLT litigation.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8982577c-9d72-4476-a2b0-1451728c0630.pdf) |
| 26 Jun - Longview Tea received reclassification requests from four promoter/promoter group entities on 25 June 2026. | [Intimation Pursunat To Regulation 31(A) Of SEBI (LODR) Regulation 2015 26 Jun - Longview Tea received reclassification requests from four promoter/promoter group entities on 25 June 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=70959120-6cee-4fdb-87aa-85514e3edc34.pdf) |
| 26 Jun - Four promoter/promoter group entities requested public reclassification on 25 June 2026. | [Intimation Pursunat To Regulation 31(A) Of SEBI (LODR) Regulation 2015 26 Jun - Four promoter/promoter group entities requested public reclassification on 25 June 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f5e88cb9-8922-4a5b-844b-4dedf1d6fa88.pdf) |
| 24 Feb - Eris partners with Natco to commercialise CDSCO-approved generic semaglutide in India; launch expected March 2026. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 24 Feb - Eris partners with Natco to commercialise CDSCO-approved generic semaglutide in India; launch expected March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ada5a8cc-9e4f-4b91-8109-529e4d9f2f06.pdf) |
| 23 Feb - Eris Lifesciences meeting Ajanta India Fund in Mumbai on 26 Feb 2026 at 10:00 AM (in-person). | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 23 Feb - Eris Lifesciences meeting Ajanta India Fund in Mumbai on 26 Feb 2026 at 10:00 AM (in-person).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/64172d41-3ac6-4dd3-8e07-939ffe958f13.pdf) |
| 20 Feb - Corporate presentation: Rs.380-400cr near-term capex; Rs.750-800cr FY26–FY28; net-debt target <1.5x by Dec-2026. | [Corporate Presentation 20 Feb - Corporate presentation: Rs.380-400cr near-term capex; Rs.750-800cr FY26–FY28; net-debt target <1.5x by Dec-2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c98a1263-5ae2-4cb4-8f41-8030d9ee07c0.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2022 | [Concall - Oct 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/79f1006e-99f9-4766-be63-a36922f8387a.pdf) |
| May 2022 | [Concall - May 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6579cb00-4865-45c5-bd01-558683663330.pdf) |
| May 2021 | [Concall - May 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e4ec3bde-d087-42bb-a12c-812935515dcb.pdf) |
| Mar 2023 | [Concall - Mar 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4cf1f0e8-b7cf-4f70-aa33-0b2e0b258cbc.pdf) |
| Jun 2020 | [Concall - Jun 2020](https://www.bseindia.com/xml-data/corpfiling/AttachHis/97d8fdb2-6318-423c-a923-41bc77f4c1a2.pdf) |
| Jan 2023 | [Concall - Jan 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/eaaac04b-0902-4030-8b88-2477f2762fc5.pdf) |
| Feb 2022 | [Concall - Feb 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/54cda3c5-e5c6-41fe-93ca-ef1db3524fc0.pdf) |
| Aug 2022 | [Concall - Aug 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0a015877-9d65-4cac-9fac-c90fdcba7da8.pdf) |
| Aug 2021 | [Concall - Aug 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ae981df5-8184-4814-844b-01aed97b9d79.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/15cd9453-3801-4719-b033-bcec14b26fdd.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ec75d137-2be3-4834-8710-45eb64a2da5d.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/22a2491c-a188-41d3-9b38-cf59ea6d198b.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c873eac8-4169-41c5-b5b2-388fd318b874.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2081cfd2-6878-4f61-aea3-950b2927c0b8.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7e02aa14-e5f1-488b-9c36-c5d631f9719c.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/540596/74122540596.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/526568/73112526568.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/540596/69274540596.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/526568/70010526568.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:59:10.150Z.